GlassScriptPhysician profile
Luisito Ago
NPI 1184356537
$1,774.34
in general payments reported to CMS, 2019-2025
26 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $646 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.37 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $156.57 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $148.00 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $124.54 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $118.97 | 2024-2025 | |
| Abbvie INC. | $93.04 | 2025 | |
| Janssen Pharmaceuticals, INC | $86.59 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $85.21 | 2025 | Rexulti |
| Lundbeck LLC | $70.79 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.39 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.79 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $45.39 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $44.10 | 2024 | Trelegy Ellipta |
| Shield Therapeutics INC | $43.11 | 2025 | |
| Aimmune Therapeutics, INC. | $38.57 | 2025 | Vowst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $37.14 | 2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.13 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.26 | 2025 | |
| Verity Pharmaceuticals INC. | $20.89 | 2025 | Tlando |
| Actelion Pharmaceuticals US, INC. | $20.76 | 2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $20.31 | 2024 | |
| Pfizer INC. | $19.06 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.33 | 2025 | Austedo Xr |
| Amgen INC. | $17.50 | 2024 | Otezla, Repatha |
| Corcept Therapeutics | $16.23 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisito Ago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.